Thyroid Cancer in Young Adults

Seminars in Oncology

Volumn 36, Issue 3, 2009, Pages 258-274

  Ying, Anita K ^a,b   Huh, Winston ^b   Bottomley, Sarah ^b   Evans, Douglas B ^b   Waguespack, Steven G ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; CARBOPLATIN; CISPLATIN; DACARBAZINE; DOXORUBICIN; GEFITINIB; IMATINIB; IODINE 131; MOTESANIB; PACLITAXEL; RADIOACTIVE IODINE; SORAFENIB; SUNITINIB; TIPIFARNIB; UNCLASSIFIED DRUG; VANDETANIB; XL 184;

ARTICLE; ASPIRATION BIOPSY; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COLON CANCER; DENTAL CARIES; DIAGNOSTIC TEST; DIARRHEA; DIFFERENTIATED THYROID CARCINOMA; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GONAD DYSFUNCTION; HUMAN; INFERTILITY; LEUKEMIA; LEUKOPENIA; LOBECTOMY; LUNG FIBROSIS; LYMPH NODE DISSECTION; NAUSEA; OLIGOSPERMIA; ONSET AGE; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; RISK REDUCTION; SALIVARY GLAND CANCER; SIALOADENITIS; SIALOLITHIASIS; SIDE EFFECT; SMELLING DISORDER; SPERMATOZOON COUNT; SPERMATOZOON MOTILITY; STOMACH CANCER; SYSTEMIC THERAPY; TASTE DISORDER; THROMBOCYTOPENIA; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; THYROIDITIS; TREATMENT INDICATION; TREATMENT OUTCOME; ULTRASOUND; VOMITING; XEROSTOMIA;

ADULT; AGE FACTORS; CARCINOMA, MEDULLARY; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 65549161768     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.03.009     Document Type: Article

References (132)

1. American Cancer Society. Cancer facts & figures 2008 (2008), American Cancer Society, Atlanta, GA
2. U.S. Cancer Statistics Working Group. United States cancer statistics: 1999-2004 incidence and mortality web-based report. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute (2008). www.cdc.gov/uscs
3. In: Ries L., Melbert D., Krapcho M., et al. (Eds). SEER cancer statistics review, 1975-2005 (2008), National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2005/ Available at: http://seer.cancer.gov/csr/1975_2005/
4. Sherman S.I. Thyroid carcinoma. Lancet 361 (2003) 501-511
5. Ain K.B. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol 16 (1999) 64-69
6. Kim T.Y., Kim K.W., Jung T.S., Kim J.M., Kim S.W., Chung K.W., et al. Prognostic factors for Korean patients with anaplastic thyroid carcinoma. Head Neck 29 (2007) 765-772
7. Kosary C. Cancer of the Thyroid. in Ries LAG YJ. In: Keel G.E., Eisner M.P., Lin Y.D., and Horner M.J. (Eds). SEER Survival Monograph: Cancer Survival Among Adults: U.S. Seer Program, 1988-2001, Patient and Tumor Characteristics (2007), National Cancer Institute, Bethesda, MD 217-226
8. Neff R.L., Farrar W.B., Kloos R.T., and Burman K.D. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 37 (2008) 525-538
9. Waguespack S., Wells S., Ross J., and Bleyer A. Thyroid cancer. In: Bleyer A., O'Leary M., Barr R., et al. (Eds). Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival 1975-2000 (2006), National Cancer Institute, Bethesda, MD 143-154
10. Lang B.H., Lo C.Y., Chan W.F., Lam K.Y., and Wan K.Y. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg 245 (2007) 366-378
11. Grubbs E.G., Rich T.A., Li G., Sturgis E.M., Younes M.N., Myers J.N., et al. Recent advances in thyroid cancer. Curr Probl Surg 45 (2008) 156-250
12. Shaha A.R. TNM classification of thyroid carcinoma. World J Surg 31 (2007) 879-887
13. AACE/AAES medical/surgical guidelines for clinical practice. management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 7 (2001) 202-220
14. British Thyroid Association and Royal College of Physicians. Guidelines for the management of thyroid cancer (2007), Royal College of Physicians, London
15. Sherman S.I., et al. NCCN thyroid carcinoma clinical practice guidelines in oncology (v.1.2008) (2008), National Comprehensive Cancer Network, Ft. Washington, PA. http://www.nccn.org Available at: http://www.nccn.org
16. Brandi M.L., Gagel R.F., Angeli A., Bilezikian J.P., Beck-Peccoz P., Bordi C., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 (2001) 5658-5671
17. Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 (2006) 109-142
18. Schlumberger M., and Pacini F. Thyroid tumors (2003), Nucleon, Paris
19. Schneider A.B. Radiation-induced thyroid cancer. UpToDate Online 16.2. 2007. www.uptodate.com
20. Boice Jr. J.D. Cancer following irradiation in childhood and adolescence. Med Pediatr Oncol Suppl 1 (1996) 29-34
21. Samaan N.A., Schultz P.N., Ordonez N.G., Hickey R.C., and Johnston D.A. A comparison of thyroid carcinoma in those who have and have not had head and neck irradiation in childhood. J Clin Endocrinol Metab 64 (1987) 219-223
22. Acharya S., Sarafoglou K., LaQuaglia M., Lindsley S., Gerald W., Wollner N., et al. Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence. Cancer 97 (2003) 2397-2403
23. Shibata Y., Yamashita S., Masyakin V.B., Panasyuk G.D., and Nagataki S. 15 years after Chernobyl: new evidence of thyroid cancer. Lancet 358 (2001) 1965-1966
24. Merchant T.E., Williams T., Smith J.M., Rose S.R., Danish R.K., Burghen G.A., et al. Preirradiation endocrinopathies in pediatric brain tumor patients determined by dynamic tests of endocrine function. Int J Radiat Oncol Biol Phys 54 (2002) 45-50
25. Sobrinho-Simoes M., Maximo V., Rocha A.S., Trovisco V., Castro P., Preto A., et al. Intragenic mutations in thyroid cancer. Endocrinol Metab Clin North Am 37 (2008) 333-362
26. Nikiforov Y.E. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 21 Suppl 2 (2008) S37-S43
27. Alberti L., Carniti C., Miranda C., Roccato E., and Pierotti M.A. RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol 195 (2003) 168-186
28. Xing M., Westra W.H., Tufano R.P., Cohen Y., Rosenbaum E., Rhoden K.J., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90 (2005) 6373-6379
29. Nikiforova M.N., Tseng G.C., Steward D., Diorio D., and Nikiforov Y.E. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 93 (2008) 1600-1608
30. Paes J.E., and Ringel M.D. Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am 37 (2008) 375-387
31. Kebebew E. Hereditary non-medullary thyroid cancer. World J Surg 32 (2008) 678-682
32. Alsanea O., Wada N., Ain K., Wong M., Taylor K., Ituarte P.H., et al. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer?. A multicenter series. Surgery 128 (2000) 1043-1051
33. Malchoff C.D., and Malchoff D.M. Familial nonmedullary thyroid carcinoma. Semin Surg Oncol 16 (1999) 16-18
34. Capezzone M., Marchisotta S., Cantara S., Busonero G., Brilli L., Pazaitou-Panayiotou K., et al. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. Endocr Relat Cancer 15 (2008) 1075-1081
35. Cavaco B.M., Batista P.F., Martins C., Banito A., do Rosario F., Limbert E., et al. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations. Endocr Relat Cancer 15 (2008) 207-215
36. Uchino S., Noguchi S., Yamashita H., Watanabe S., Ogawa T., Tsuno A., et al. Mutational analysis of the APC gene in cribriform-morula variant of papillary thyroid carcinoma. World J Surg 30 (2006) 775-779
37. Patel S.G., Escrig M., Shaha A.R., Singh B., and Shah J.P. Management of well-differentiated thyroid carcinoma presenting within a thyroglossal duct cyst. J Surg Oncol 79 (2002) 134-139
38. Salvatori M., Saletnich I., Rufini V., Dottorini M.E., Corsello S.M., Troncone L., et al. Severe thyrotoxicosis due to functioning pulmonary metastases of well-differentiated thyroid cancer. J Nucl Med 39 (1998) 1202-1207
39. Katoh R., Sasaki J., Kurihara H., Suzuki K., Iida Y., and Kawaoi A. Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients. Cancer 70 (1992) 1585-1590
40. Kouvaraki M.A., Shapiro S.E., Fornage B.D., Edeiken-Monro B.S., Sherman S.I., Vassilopoulou-Sellin R., et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 134 (2003) 946-954
41. Vassilopoulou-Sellin R., Klein M.J., Smith T.H., Samaan N.A., Frankenthaler R.A., Goepfert H., et al. Pulmonary metastases in children and young adults with differentiated thyroid cancer. Cancer 71 (1993) 1348-1352
42. Bilimoria K.Y., Bentrem D.J., Ko C.Y., Stewart A.K., Winchester D.P., Talamonti M.S., et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 246 (2007) 375-381
43. Musacchio M.J., Kim A.W., Vijungco J.D., and Prinz R.A. Greater local recurrence occurs with "berry picking" than neck dissection in thyroid cancer. Am Surg 69 (2003) 191-196
44. Kupferman M.E., Patterson D.M., Mandel S.J., LiVolsi V., and Weber R.S. Safety of modified radical neck dissection for differentiated thyroid carcinoma. Laryngoscope 114 (2004) 403-406
45. Sosa J.A., Bowman H.M., Tielsch J.M., Powe N.R., Gordon T.A., and Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 228 (1998) 320-330
46. Taylor T., Specker B., Robbins J., Sperling M., Ho M., Ain K., et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 129 (1998) 622-627
47. Mazzaferri E.L., and Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97 (1994) 418-428
48. Durante C., Haddy N., Baudin E., Leboulleux S., Hartl D., Travagli J.P., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91 (2006) 2892-2899
49. Jonklaas J., Sarlis N.J., Litofsky D., Ain K.B., Bigos S.T., Brierley J.D., et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16 (2006) 1229-1242
50. Tuttle R.M., Brokhin M., Omry G., Martorella A.J., Larson S.M., Grewal R.K., et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 49 (2008) 764-770
51. Pacini F., Ladenson P.W., Schlumberger M., Driedger A., Luster M., Kloos R.T., et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91 (2006) 926-932
52. Tuttle R.M., Leboeuf R., Robbins R.J., Qualey R., Pentlow K., Larson S.M., et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 47 (2006) 1587-1591
53. Brierley J.D., and Tsang R.W. External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin North Am 37 (2008) 497-509
54. Sheils O.M., and Sweeney E.C. TSH receptor status of thyroid neoplasms-TaqMan RT-PCR analysis of archival material. J Pathol 188 (1999) 87-92
55. Pujol P., Daures J.P., Nsakala N., Baldet L., Bringer J., and Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 81 (1996) 4318-4323
56. McGriff N.J., Csako G., Gourgiotis L., Lori C.G., Pucino F., and Sarlis N.J. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 34 (2002) 554-564
57. Biondi B., Filetti S., and Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 1 (2005) 32-40
58. Cooper D.S. Approach to the patient with subclinical hyperthyroidism. J Clin Endocrinol Metab 92 (2007) 3-9
59. Spencer C.A., Takeuchi M., Kazarosyan M., Wang C.C., Guttler R.B., Singer P.A., et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 83 (1998) 1121-1127
60. Chiovato L., Latrofa F., Braverman L.E., Pacini F., Capezzone M., Masserini L., et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 139 (2003) 346-351
61. Mazzaferri E.L., Robbins R.J., Spencer C.A., Braverman L.E., Pacini F., Wartofsky L., et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88 (2003) 1433-1441
62. Kloos R.T., and Mazzaferri E.L. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 90 (2005) 5047-5057
63. Castagna M.G., Brilli L., Pilli T., Montanaro A., Cipri C., Fioravanti C., et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 93 (2008) 76-81
64. Pacini F., Capezzone M., Elisei R., Ceccarelli C., Taddei D., and Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87 (2002) 1499-1501
65. Kloos R.T. Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer. J Clin Endocrinol Metab 93 (2008) 1519-1525
66. 18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91 (2006) 498-505
67. Khan N., Oriuchi N., Higuchi T., Zhang H., and Endo K. PET in the follow-up of differentiated thyroid cancer. Br J Radiol 76 (2003) 690-695
68. Baudin E., and Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 8 (2007) 148-156
69. Polverino A., Coxon A., Starnes C., Diaz Z., DeMelfi T., Wang L., et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66 (2006) 8715-8721
70. Rosen L.S., Kurzrock R., Mulay M., Van Vugt A., Purdom M., Ng C., et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 25 (2007) 2369-2376
71. Sherman S.I. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am 37 (2008) 511-524
72. Gupta-Abramson V., Troxel A.B., Nellore A., Puttaswamy K., Redlinger M., Ransone K., et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26 (2008) 4714-4719
73. Kloos R., Ringel M., Knopp M., Heverhagen J., Rittenberry J., Weldy L., et al. Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): updated results of a phase II study. J Clin Oncol 24 (2006) 5534
74. Cohen E.E., Rosen L.S., Vokes E.E., Kies M.S., Forastiere A.A., Worden F.P., et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26 (2008) 4708-4713
75. Dawson S.J., Conus N.M., Toner G.C., Raleigh J.M., Hicks R.J., McArthur G., et al. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs 19 (2008) 547-552
76. Roman S., Lin R., and Sosa J.A. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107 (2006) 2134-2142
77. Jimenez C., Hu M.I., and Gagel R.F. Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am 37 (2008) 481-496
78. Elisei R., Cosci B., Romei C., Bottici V., Renzini G., Molinaro E., et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93 (2008) 682-687
79. Machens A. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 350 (2004) 943
80. Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshima K., Lairmore T.C., et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2 (1993) 851-856
81. Mulligan L.M., Kwok J.B., Healey C.S., Elsdon M.J., Eng C., Gardner E., et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 (1993) 458-460
82. Carlson K.M., Dou S., Chi D., Scavarda N., Toshima K., Jackson C.E., et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A 91 (1994) 1579-1583
83. Moley J.F., and DeBenedetti M.K. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 229 (1999) 880-887
84. Yen T.W., Shapiro S.E., Gagel R.F., Sherman S.I., Lee J.E., and Evans D.B. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 134 (2003) 890-899
85. Brierley J., Tsang R., Simpson W.J., Gospodarowicz M., Sutcliffe S., and Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6 (1996) 305-310
86. Fife K.M., Bower M., and Harmer C.L. Medullary thyroid cancer: the role of radiotherapy in local control. Eur J Surg Oncol 22 (1996) 588-591
87. Schwartz D.L., Rana V., Shaw S., Yazbeck C., Ang K.K., Morrison W.H., et al. Postoperative radiotherapy for advanced medullary thyroid cancer-local disease control in the modern era. Head Neck 30 (2008) 883-888
88. Barbet J., Campion L., Kraeber-Bodere F., and Chatal J.F. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90 (2005) 6077-6084
89. Laure Giraudet A., Al Ghulzan A., Auperin A., Leboulleux S., Chehboun A., Troalen F., et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158 (2008) 239-246
90. Giraudet A.L., Vanel D., Leboulleux S., Auperin A., Dromain C., Chami L., et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 92 (2007) 4185-4190
91. Quayle F.J., and Moley J.F. Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes. J Surg Oncol 89 (2005) 122-129
92. de Groot J.W., Zonnenberg B.A., van Ufford-Mannesse P.Q., de Vries M.M., Links T.P., Lips C.J., et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92 (2007) 3466-3469
93. Frank K., Raue F., Gottswinter J., Heinrich U., Meybier H., and Ziegler R. Importance of early diagnosis and follow-up in multiple endocrine neoplasia (MEN II B). Eur J Pediatr 143 (1984) 112-116
94. Wells Jr. S.A., Gosnell J.E., Gagel R.F., Moley J.F., Pfister D.G., Sosa J.A., et al. Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial [abstract]. J Clin Oncol (Meeting Abstracts) 25 (2007) 6018
95. Schlumberger M., Elise R., Sherman S.I., et al. Initial results from a phase 2 trial of motesanib diphosphate (AMG 706) in patients with medullary thyroid cancer. Presented at 89th Annual Meeting of the Endocrine Society (June 2007) Toronto, Canada
96. Pennell N.A., Daniels G.H., Haddad R.I., Ross D.S., Evans T., Wirth L.J., et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18 (2008) 317-323
97. Kober F., Hermann M., Handler A., and Krotla G. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer [abstract]. J Clin Oncol (Meeting Abstracts) 25 (2007) 14065
98. Hong D., Ye L., Gagel R., Chintala L., El Naggar A.K., Wright J., et al. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 7 (2008) 1001-1006
99. Kelleher F.C., and McDermott R. Response to sunitinib in medullary thyroid cancer. Ann Intern Med 148 (2008) 567
100. Salgia R., Sherman S., Hong D.S., Ng C.S., Frye J., Janisch L., et al. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC) [abstract]. J Clin Oncol (Meeting Abstracts) 26 (2008) 3522
101. Smith L.H., Danielsen B., Allen M.E., and Cress R. Cancer associated with obstetric delivery: results of linkage with the California Cancer Registry. Am J Obstet Gynecol 189 (2003) 1128-1135
102. Moosa M., and Mazzaferri E.L. Outcome of differentiated thyroid cancer diagnosed in pregnant women. J Clin Endocrinol Metab 82 (1997) 2862-2866
103. Abalovich M., Amino N., Barbour L.A., Cobin R.H., De Groot L.J., Glinoer D., et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 92 (2007) S1-S47
104. Yasmeen S., Cress R., Romano P.S., Xing G., Berger-Chen S., Danielsen B., et al. Thyroid cancer in pregnancy. Int J Gynaecol Obstet 91 (2005) 15-20
105. Thomas A.K., McVie R., and Levine S.N. Disorders of maternal calcium metabolism implicated by abnormal calcium metabolism in the neonate. Am J Perinatol 16 (1999) 515-520
106. Leboeuf R., Emerick L.E., Martorella A.J., and Tuttle R.M. Impact of pregnancy on serum thyroglobulin and detection of recurrent disease shortly after delivery in thyroid cancer survivors. Thyroid 17 (2007) 543-547
107. Rosario P.W., Barroso A.L., and Purisch S. The effect of subsequent pregnancy on patients with thyroid carcinoma apparently free of the disease. Thyroid 17 (2007) 1175-1176
108. Alexander E.K., Marqusee E., Lawrence J., Jarolim P., Fischer G.A., and Larsen P.R. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. N Engl J Med 351 (2004) 241-249
109. Kamari Y., Sharabi Y., Leiba A., Peleg E., Apter S., and Grossman E. Peripartum hypertension from pheochromocytoma: a rare and challenging entity. Am J Hypertens 18 (2005) 1306-1312
110. Sawka A.M., Lakra D.C., Lea J., Alshehri B., Tsang R.W., Brierley J.D., et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf) 69 (2008) 479-490
111. Sawka A.M., Lea J., Alshehri B., Straus S., Tsang R.W., Brierley J.D., et al. A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin Endocrinol (Oxf) 68 (2008) 610-617
112. Pacini F., Schlumberger M., Dralle H., Elisei R., Smit J.W., and Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154 (2006) 787-803
113. 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. J Nucl Med 49 (2008) 845-852
114. van Santen H.M., Aronson D.C., Vulsma T., Tummers R.F., Geenen M.M., de Vijlder J.J., et al. Frequent adverse events after treatment for childhood-onset differentiated thyroid carcinoma: a single institute experience. Eur J Cancer 40 (2004) 1743-1751
115. Schultz P.N., Stava C., and Vassilopoulou-Sellin R. Health profiles and quality of life of 518 survivors of thyroid cancer. Head Neck 25 (2003) 349-356
116. Meier D.A., Brill D.R., Becker D.V., Clarke S.E., Silberstein E.B., Royal H.D., et al. Procedure guideline for therapy of thyroid disease with (131)iodine. J Nucl Med 43 (2002) 856-861
117. Mandel S.J., and Mandel L. Radioactive iodine and the salivary glands. Thyroid 13 (2003) 265-271
118. Nakada K., Ishibashi T., Takei T., Hirata K., Shinohara K., Katoh S., et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?. J Nucl Med 46 (2005) 261-266
119. Subramanian S., Goldstein D.P., Parlea L., Thabane L., Ezzat S., Ibrahim-Zada I., et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 17 (2007) 1277-1288
120. Brown A.P., Chen J., Hitchcock Y.J., Szabo A., Shrieve D.C., and Tward J.D. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 93 (2008) 504-515
121. Canchola A.J., Horn-Ross P.L., and Purdie D.M. Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol 163 (2006) 521-527
122. Zarnegar R., Brunaud L., and Clark O.H. Prevention, evaluation, and management of complications following thyroidectomy for thyroid carcinoma. Endocrinol Metab Clin North Am 32 (2003) 483-502
123. Roh J.L., Yoon Y.H., and Park C.I. Recurrent laryngeal nerve paralysis in patients with papillary thyroid carcinomas: evaluation and management of resulting vocal dysfunction. Am J Surg (2008) Epub ahead of print
124. Biondi B., Fazio S., Carella C., Amato G., Cittadini A., Lupoli G., et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 77 (1993) 334-338
125. Mercuro G., Panzuto M.G., Bina A., Leo M., Cabula R., Petrini L., et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab 85 (2000) 159-164
126. Shapiro L.E., Sievert R., Ong L., Ocampo E.L., Chance R.A., Lee M., et al. Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. J Clin Endocrinol Metab 82 (1997) 2592-2595
127. Padayatty S. Concerning minimal cardiac effects in asymptomatic athyreotic patients treated with thyrotropin-suppressive doses of L-thyroxine. J Clin Endocrinol Metab 83 (1998) 2607-2608
128. Mendoza A., Shaffer B., Karakla D., Mason M.E., Elkins D., and Goffman T.E. Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. Thyroid 14 (2004) 133-140
129. Escobar-Morreale H.F., Botella-Carretero J.I., Escobar del Rey F., and Morreale de Escobar G. Review: treatment of hypothyroidism with combinations of levothyroxine plus liothyronine. J Clin Endocrinol Metab 90 (2005) 4946-4954
130. Eustatia-Rutten C.F., Corssmit E.P., Pereira A.M., Frolich M., Bax J.J., Romijn J.A., et al. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. Clin Endocrinol (Oxf) 64 (2006) 284-291
131. Sherman S.I., Wirth L.J., Droz J.P., Hofmann M., Bastholt L., Martins R.G., et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359 (2008) 31-42
132. Frank-Raue K., Fabel M., Delorme S., Haberkorn U., and Raue F. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 157 (2007) 215-220